Mr. Hall served as CEO and President of RepliCel Life Sciences from 2012 through 2015. During that time, RepliCel’s cell therapy work grew from a single program to three, alongside development of the DermaPrecise™ dermal injector. Previously, Mr. Hall consulted to government, the pharmaceutical industry, biotech, eHealth and NGOs for two years. For the prior 15 years, he served in multiple roles at Angiotech Pharmaceuticals Inc., including CFO, CCO, Treasurer and Secretary.
Mr. Hall is a Past Chair and board member of Life Sciences BC and a director of Providence Health Care Research Institute and VANC Pharmaceuticals. He is the author of Life Sciences BC’s position papers for the Premier’s Competition Council Report and Conversation on Health. Mr. Hall was also a member of the BC Task Force on PharmaCare and serves on the board of directors of Advantage BC. He holds an Honours degree in Economics and Finance from the University of Manitoba.
Mr. Hall serves as the Chairman of RepliCel’s Board of Directors.